Oral Cancer News – Page 274 – The Oral Cancer Foundation News Archive

Routine Oesophageal Screening Recommended for Patients Previously Treated for Head and Neck Cancer: Presented at AAO-HNSF

Source: Docguide.com By Kristina Rebelo SAN DIEGO -- October 12, 2009 -- Patients who have been treated for head and neck cancer (HNCA) should be screened for oesophageal pathologies about 3 months out whether they are symptomatic or not, according a poster presentation here October 4 at the American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting 2009. Oesophageal pathology is extremely common in patients who have been treated for HNCA, according to the researchers. "When we talk about HNCA, the 5-year survival rate for this cancer is 50%," Peter C. Belafsky, MD, Head and Neck Oncological Surgery, University of California at Davis, and the Voice and Swallowing Center, Davis, California, told DocGuide. "We took a look at the oesophagus in patients after treatment for head and neck cancer and we did oesophagoscopy and biopsy, as indicated, on all of them. We successfully performed the oesophagoscopy on all 100 patients without complication and we had only 13% of the entire cohort who had a normal examination." The study included 100 patients who had chemoradiation and underwent follow-up oesophagoscopy. Patient demographics, symptom surveys, treatments received, reflux medications prescribed and oesophageal findings were prospectively determined. Findings on oesophagoscopy included stricture (22%), candidiasis (9%), peptic oesophagitis (67%), Barrett's (8%), and new primary tumours -- 1 hypopharynx, 2 oesophageal, and 1 stomach (4%); 13% had a normal oesophagoscopy. The mean age of the cohort was 64 years and 74% were male. The mean time between the cessation of treatment and endoscopy was 40 [...]

Charlotte Parker2009-10-13T10:26:11-07:00October, 2009|Oral Cancer News|

Surgical scalpel sniffs out cancer

Source: www.technologyreview.com Author: Katherine Bourzac In the hope of helping oncologists remove every piece of tumor tissue during surgery, researchers are developing new imaging tools that work in real time in the operating room. European researchers have now demonstrated that a chemical analysis instrument called a mass spectrometer can be coupled with an electroscalpel to create a molecular profile of tissue during surgery. The researchers have shown that the method can be used to map out different tissue types and distinguish cancerous tissue. The device will begin clinical trials next month. "When a surgeon is performing cancer surgery, he doesn't have any direct information on where the tumor is," says Zoltán Takáts, a professor at Justus-Liebig University in Giessen, Germany. Instead, surgeons rely on preoperative imaging scans and on feedback from pathologists examining tissue biopsies under a microscope. "We want to provide a tool that's right in their hands, so that if they think a structure looks suspicious, they can just test it," says Takáts. Takáts realized that some surgical cutting tools, including electroscalpels, produce gaseous ions as a kind of waste product that are suitable for analysis with mass spectrometry. And these fumes, often called "surgical smoke," are already collected during surgery because they're harmful to the lungs. Takáts and his collaborators found that mass spectrometry of surgical smoke can be used to make a molecular map of a tumor. After the fumes are sucked into the mass spectrometer, the chemicals in the sample are identified and checked against [...]

Oral Cancer Foundation News Team - A2009-10-13T03:49:46-07:00October, 2009|Oral Cancer News|

Today’s smokeless tobacco is just as addictive and marketed to the young

Source: www.timesleader.com Author: Geri Anne Kaikowski It’s a misconception that just because you don’t smoke nicotine, it is less addictive and less dangerous than a cigarette. That’s the fallacy and danger behind a marketing ploy for a new take on a centuries old product, snuff. Whereas the old snuff, popular in the 1970s and 1980s in round paper containers or bags under the name Copenhagen or Skoal, was chewed and spit out, today’s snuff comes in fancy containers with equally avant-garde aromas and names. And unlike its predecessor, this snuff isn’t pinched into one’s gums or chewed, it’s inhaled through the nostrils. And it isn’t being used just by baseball players or teenage boys emulating their sports idols. Snuff is being marketed to tweens, teens and college students, both female and male, as hip, cool and healthy. It’s available for a nominal cost with a simple click online. Yet, it’s anything but harmless, according to an area ear, nose and throat specialist, who is concerned that in any form, nicotine is extremely addictive. And what makes snuff so dangerous is that it doesn’t fall under any federal regulations, according to a local tobacco expert. Many feel it’s the burning and inhaling of tobacco that exposes users to most carcinogens. Some specialists feel that, for health reasons, if you are going to use tobacco, you are better off using nasal snuff. But nasal snuff contains nicotine and is highly addictive, says Dr. Zephron Newmark, an ENT specialist with Geisinger [...]

Oral Cancer Foundation News Team - A2009-10-13T03:44:09-07:00October, 2009|Oral Cancer News|

Routine oesophageal screening recommended for patients previously treated for head and neck cancer

Source: www.docguide.com Author: Kristina Rebelo Patients who have been treated for head and neck cancer (HNCA) should be screened for oesophageal pathologies about 3 months out whether they are symptomatic or not, according a poster presentation here October 4 at the American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF) Annual Meeting 2009. Oesophageal pathology is extremely common in patients who have been treated for HNCA, according to the researchers. "When we talk about HNCA, the 5-year survival rate for this cancer is 50%," Peter C. Belafsky, MD, Head and Neck Oncological Surgery, University of California at Davis, and the Voice and Swallowing Center, Davis, California, told DocGuide. "We took a look at the oesophagus in patients after treatment for head and neck cancer and we did oesophagoscopy and biopsy, as indicated, on all of them. We successfully performed the oesophagoscopy on all 100 patients without complication and we had only 13% of the entire cohort who had a normal examination." The study included 100 patients who had chemoradiation and underwent follow-up oesophagoscopy. Patient demographics, symptom surveys, treatments received, reflux medications prescribed and oesophageal findings were prospectively determined. Findings on oesophagoscopy included stricture (22%), candidiasis (9%), peptic oesophagitis (67%), Barrett's (8%), and new primary tumours -- 1 hypopharynx, 2 oesophageal, and 1 stomach (4%); 13% had a normal oesophagoscopy. The mean age of the cohort was 64 years and 74% were male. The mean time between the cessation of treatment and endoscopy was 40 months and 77% of the HNCA [...]

Oral Cancer Foundation News Team - A2009-10-12T12:05:11-07:00October, 2009|Oral Cancer News|

Giving Gardasil to boys not worth the cost?

Source: HealthDay.com Author: Steven Reinberg But other experts dispute finding, and say young men need protection from STDs THURSDAY, Oct. 8 (HealthDay News) -- The cost of giving boys the human papillomavirus (HPV) vaccine would outweigh any health benefit, researchers say. Last month, a U.S. Food and Drug Administration panel recommended expanding use of the Gardasil vaccine to males aged 9 to 26 to protect them from genital warts, but the cost effectiveness of such a program was unclear at the time. But researchers from the Harvard School of Public Health conducted such an analysis comparing a girls-only vaccination program with a co-ed vaccination program. Currently, Gardasil is approved for girls aged 9 and over to protect them from cervical cancer. "This study found that while vaccine coverage and efficacy are high in girls, including boys in an HPV vaccination program generally exceeds what the U.S. typically considers good value for money," said lead researcher Jane Kim, an assistant professor of health decision science. The report is published in the Oct. 9 online edition of the British Medical Journal. Vaccination was considered a good value if cost-effectiveness ratios ranged from $50,000 to $100,000 per quality-adjusted life year, meaning the cost of the vaccine vs. the number of added years someone would gain by getting the vaccine. Assuming 75 percent coverage and lifelong protection, the researchers found routine vaccination of 12-year-old girls was a good value at less than $50,000 per quality-adjusted life year. However, adding preadolescent boys increased the cost-effectiveness ratio [...]

Charlotte Parker2009-10-12T11:54:27-07:00October, 2009|Oral Cancer News|

Rare head and neck cancer linked to HPV, study finds

Source: esciencenews.com Author: staff An increase in cases of a rare type of head and neck cancer appears to be linked to HPV, or human papillomavirus, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center. The study looked at patients with nasopharyngeal cancer, a tumor that grows behind the nose and at the top of the throat, above the tonsils. This rare cancer occurs in less than 1 of every 100,000 Americans. "Though rare, this is the first report of nasopharyngeal cancer being caused by the HPV epidemic. We are in the middle of a tonsil cancer epidemic, seeing many patients with tonsil cancer linked to HPV. It turns out that HPV may also be a new cause of this rare form of cancer that occurs in this hidden location," says study author Carol Bradford, M.D., professor and chair of otolaryngology at the U-M Medical School. In the study, which appears online in the journal Head & Neck, the researchers looked at tissue samples taken before treatment for either nasopharyngeal cancer or tonsil cancer. Of the 89 patients in the study, five had nasopharyngeal cancer, and four of those were positive for HPV. At the same time, the four HPV-positive tumors were also all negative for Epstein-Barr virus, which has previously been one of the biggest infectious causes of nasopharyngeal cancer. "Since I began studying head and neck cancer, I have wondered what the cause of Epstein-Barr virus-negative nasopharyngeal tumors might be. This research [...]

Oral Cancer Foundation News Team - A2009-10-09T11:01:48-07:00October, 2009|Oral Cancer News|

Avaxia Biologics awarded phase I SBIR grant to develop antibody therapeutic for oral mucositis

Source: www.reuters.com Author: press release Avaxia Biologics, Inc., a biotechnology company developing oral antibodies for disease targets accessible via the GI tract, announced today that it has been awarded a Phase I SBIR grant from the National Institute of Dental and Craniofacial Research to support the development of a novel antibody therapeutic for oral mucositis. Avaxia is developing a polyclonal anti-TNF antibody to be administered to the oral cavity of patients suffering from mucositis. The antibody is designed to reduce the pain and ulceration associated with this serious side effect of cancer treatment. The grant will fund key pre-clinical studies of the antibody in a well-established animal model of radiation-induced oral mucositis. "We are delighted to have been awarded this grant from the NIH," said Barbara S. Fox, Avaxia's founder and CEO. "Our preliminary data indicate that an anti-TNF antibody, delivered topically to a damaged mucosal membrane, will limit the severity of the inflammatory response induced by ionizing radiation. The support of the NIH provides both the funding we need to advance the development of this much needed therapeutic, and critical scientific validation of our approach." Avaxia is carrying out the grant-funded research in collaboration with Biomodels LLC, a Watertown-based pre-clinical drug research organization. Biomodels specializes in animal models of toxicities associated with chemotherapy and radiation therapy used for the treatment of cancer and is a world leader in the study of cancer treatment-related mucosal injury (mucositis). "We are looking forward to working closely with Avaxia Biologics scientists in developing [...]

Oral Cancer Foundation News Team - A2009-10-08T21:22:07-07:00October, 2009|Oral Cancer News|

A perk for coffee lovers: Java may lower oral cancer risk

Source: Scientificamerican.com Author: Katherine Harmon Raise high the coffee bean! Good news, coffee-drinkers: a new study shows your beverage of choice may lower your chances of getting oral, esophageal and pharyngeal (back-of-the-throat) cancer. Japanese researchers report in the American Journal of Epidemiology this week that people they studied who drank a cup or more of Joe daily had about a 50 percent less chance than non-imbibers of developing these cancers. The scientists based their findings on 13 years of data of some 38,000 people ages 40 to 64 with no history of cancer. According to the study, coffee drinking lowered the odds of these types of cancer even in people with high-risk behaviors (read: smoking and boozing). "Caffeine has been suggested to suppress the progression of tumor cells," senior study author Toru Naganuma, an epidemiological researcher at Japan's Tohoku University, toldScientificAmerican.com in an email. He noted that other studies have also linked moderate coffee drinking to reduced risk of liver cancer. "The evidence is pretty strong" in this research, says Ann Gillenwater, a professor of head and neck surgery at the University of Texas M.D. Anderson Cancer Center in Houston, who was not involved in this study. But that doesn't mean you should start downing double espressos hourly. Recent research suggests that too much caffeine can lead to insomnia, anxiety and might up the risk of miscarriage in the early stages of pregnancy. Besides, the study authors point out, caffeine alone is not the answer, noting that "high-level consumption of fresh vegetables and fruit" have also been linked to lower [...]

Charlotte Parker2009-10-09T11:05:27-07:00October, 2009|Oral Cancer News|

Artists transform symbols of pain into objects of beauty

Source: Gazette.net Author: Jason Tomassini Radiation masks showcase courage of patients Lying on a table in Cookie Kerxton's tiny Bethesda art studio is a symbol of unparalleled pain and suffering: a white, plastic mask of her own face she wore during treatment for throat cancer. The loss of speech, being fed through her stomach, the severe dry mouth, the burns on her neck — the mask serves as a reminder of her lowest moments, spent strapped to an operating table with the mask covering her face and bolted to the table, the radiation blasting away at the malignant polyps that lined her throat. "You're only there for about 10 minutes," Kerxton, 73, said last week at the Upstairs Art Studio on St. Elmo Avenue. "But it's really not fun." When Kerxton beat her cancer, after four long months of chemotherapy in 2008, she wanted to keep the radiation mask, a bland but morbid piece of plastic that Kerxton said her friends call "ghoulish." Since, Kerxton gathered more than 100 radiation masks from area hospitals and found more than 100 artists from across the country to turn the masks into pieces of art, rather than symbols of pain. "It's taking something ‘ghoulish' and making it something someone would want to have on their wall," Kerxton said. In September, Kerxton's exhibit, called "Courage Unmasked," debuted before more than 500 people at a fundraiser and live auction at the Katzen Arts Center at American University. The roughly 40 masks still for sale will be exhibited starting [...]

Charlotte Parker2009-10-08T11:25:04-07:00October, 2009|Oral Cancer News|

British celebs back drive for new cancer treatment

Source: news.sky.com/skynews Author: staff Sir Alex Ferguson and Sir David Frost are among a host of celebrities giving their support to a cancer charity campaigning for a new type of treatment to be made available nationwide. The personalities are urging people to donate to medical trials of Photodynamic Therapy which, they say, could revolutionise cancer treatment in the UK and around the world. Killing Cancer (http://www.killingcancer.co.uk/) is aiming to raise £50m to fund further trials into Photo Dynamic Therapy, a treatment that tackles some forms of cancer by killing cells through a combination of drugs and light. The treatment is a form of laser that starves the cancer of oxygen, allowing the body to heal and create new, healthy cells. Its supporters say a single 20-minute session avoids the need for invasive surgery and the traumatic effects of chemotherapy and radiotherapy. It is also, they argue, cost-effective - for example, a skin cancer treatment would amount to just £235, far less than other more traditional treatments. Other well-known names supporting the charity include Chris Tarrant, Robert Plant, Jenny Seagrove and Roger Daltrey. They are sending more than 200 million personal emails to fans and supporters, asking for funds to be allocated to their choice of one of half a dozen PDT trials. "Both my mother and father died of cancer," said Manchester United manager Sir Alex. "I think PDT is an amazing first-step option before resorting to surgery. "More patients should have access to it in our hospitals [...]

Oral Cancer Foundation News Team - A2009-10-07T14:52:47-07:00October, 2009|Oral Cancer News|